Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
NEW YORK, April 25, 2024 - Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (Tiziana or the Company), a biotechnology company renowned for its pioneering immunomodulation therapies utilizing innovative drug delivery systems, has unveiled groundbreaking statistical data demonstrating significant improvements in White Matter Z-scores in patients with non-active secondary progressive multiple sclerosis (na-SPMS) following treatment with nasal foralumab. These White Matter Z-scores serve as a crucial metric in neuroimaging studies, assessing the structural integrity of the brain and detecting any irregularities.
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, resulting in a variety of debilitating symptoms such as impaired coordination, muscle weakness, and cognitive decline. Secondary progressive multiple sclerosis (SPMS) is a more advanced stage of the disease, characterized by a gradual worsening of symptoms and a limited response to conventional treatment options.
In recent years, Tiziana Life Sciences has been at the forefront of revolutionizing MS treatment through its innovative immunomodulation therapies. By employing novel routes of drug delivery, Tiziana has successfully developed nasal foralumab, a groundbreaking treatment option for patients with na-SPMS. Foralumab, a fully-human anti-CD3 monoclonal antibody, possesses the remarkable ability to mitigate damaging immune responses while preserving crucial components of the immune system.
In their latest announcement, Tiziana revealed compelling quantitative data based on neuroimaging studies, specifically PET (Positron Emission Tomography) images, taken at the three-month mark from patients undergoing nasal foralumab treatment. These PET images provide invaluable insights into the brain’s structures and offer a comprehensive evaluation of its integrity.
The results were highly encouraging, showcasing a significant improvement in White Matter Z-scores in patients treated with nasal foralumab. This improvement signifies a restoration of brain integrity and reduction in abnormalities observed in the white matter, a area of the brain comprised of nerve fibers responsible for transmitting signals between different regions of the central nervous system. As such, the positive neuroimaging scores provide substantial evidence of foralumab’s potential to mitigate the progression of na-SPMS and improve patients’ quality of life.
The implications of these findings are immense for individuals suffering from na-SPMS, as there has been a pressing need for effective treatment options to address the disease’s debilitating consequences. Currently, most available treatments solely aim at managing symptoms and delaying the progression of the disease. However, Tiziana’s nasal foralumab presents a paradigm shift, actively targeting the root cause with its specialized immunomodulation approach.
By delivering foralumab directly to the nasal cavity, Tiziana ensures precise and efficient drug administration, maximizing therapeutic benefits while minimizing systemic side effects. This novel route of drug delivery offers improved patient compliance, convenience, and potentially reduced healthcare costs.
Dr. Gabriele Cerrone, Chairman of Tiziana Life Sciences, expressed enthusiasm regarding these neuroimaging results. He stated, We are thrilled to witness these promising outcomes in patients with na-SPMS undergoing nasal foralumab treatment. It reinforces our belief in the potential of targeted immunomodulation strategies to revolutionize multiple sclerosis therapy.
These findings represent a significant milestone for Tiziana Life Sciences and mark a potential turning point in the treatment of na-SPMS. As more data is gathered and further clinical trials are conducted, it is increasingly evident that nasal foralumab holds the promise to provide a breakthrough therapy for individuals living with multiple sclerosis.
In conclusion, Tiziana’s groundbreaking immunomodulation therapy, through the novel administration of nasal foralumab, has demonstrated positive neuroimaging results and remarkable improvements in White Matter Z-scores in patients with na-SPMS. This development signifies a potential advance towards more effective management of MS, offering hope for patients worldwide.
Comments